Wuhan YZY Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
Wuhan YZY Biopharma has a total shareholder equity of CN¥49.6M and total debt of CN¥119.5M, which brings its debt-to-equity ratio to 241%. Its total assets and total liabilities are CN¥260.0M and CN¥210.4M respectively.
Key information
241.0%
Debt to equity ratio
CN¥119.50m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥161.85m |
| Equity | CN¥49.59m |
| Total liabilities | CN¥210.37m |
| Total assets | CN¥259.96m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 2496's short term assets (CN¥210.9M) exceed its short term liabilities (CN¥170.1M).
Long Term Liabilities: 2496's short term assets (CN¥210.9M) exceed its long term liabilities (CN¥40.3M).
Debt to Equity History and Analysis
Debt Level: 2496 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2496's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2496 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2496 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.3% each year